Douglas J. Hughes
Known title: DirectorCIK: 0001710863
Associated companies
Transaction History
| IMVT | ▲ Buy | Grant | 13,880 | $0 | 4/7/2026 | View on chart |
| IMVT | ▼ Sell | Open Market | 1,909 | $46K | 12/1/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 13,091 | $303K | 12/1/2025 | View on chart |
| IMVT | ▲ Buy | Grant | 16,188 | $0 | 4/1/2025 | View on chart |
| IMVT | ▼ Sell | Open Market | 5,425 | $155K | 12/2/2024 | View on chart |
| IMVT | ▲ Buy | Grant | 11,255 | $0 | 4/2/2024 | View on chart |
| IMVT | ▲ Buy | Grant | 12,523 | $0 | 4/12/2023 | View on chart |
| IMVT | ▲ Buy | Grant | 21,059 | $0 | 8/17/2022 | View on chart |
| IMVT | ▲ Buy | Grant | 21,726 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Immunovant (IMVT) releases Q1 2027 earnings call transcript
Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.
Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.